TrialCardiovascular diabetology2025

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.

Peter Rossing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.